Kythera Biopharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 92   

Articles published

KYTH 74.98
price chart
Shares of Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) Sees Large Outflow of ...
Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) had an volatile session and gained 0.01 points till last call. The price was at $74.94, gaining 0.01% till the last intraday data.
Kythera Biopharmaceuticals Inc (KYTH) Files Form 4 Insider Selling : Iii ...  Insider Trading Report
Company Shares of Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) Rally 0.01%  American Trade Journal
Why Kythera Biopharmaceuticals, Inc Rocketed Higher
What's happening: Shares of Kythera Biopharmaceuticals (NASDAQ:KYTH) soared higher by as much as 20% ahead of a key FDA advisory panel committee meeting next week.
FDA staff backs injection to reduce double chin  Reuters
Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) Chief Financial Officer John ...
An insider of the company Kythera Biopharmaceuticals Inc, John Smither also its Chief Financial Officer, disclosed his trade activities with the Washington-based SEC on September 24, 2015.
Kythera Biopharmaceuticals Inc (KYTH) Files Form 4 Insider Selling : Keith ...  Insider Trading Report
The Chief Commercial Officer of Kythera Biopharmaceuticals Inc (NASDAQ:KYTH ...
Ratings and Sentiment Update on Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH)
Shares of Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) have been given a Buy-Sell rating of N/A by Zacks Research.
Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) Analyst Rating Update
Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) has received a hold rating for the short term, according to the latest rank of 3 from research firm, Zacks.
Insider Trading: Iii Beddingfield Sold 110638 Shares of Kythera ...
Kythera Biopharmaceuticals Inc (NASDAQ:KYTH)'s Chief Medical Officer Iii ...
Allergan to Buy Kythera Biopharmaceuticals for $2.1 Billion
Allergan Plc, the maker of wrinkle treatment Botox, agreed to buy Kythera Biopharmaceuticals Inc. for about $2.1 billion to add treatments for double chins and male pattern baldness.
Why Kythera Biopharmaceuticals, Inc. Stock Soared Today  Motley Fool
Material News For Kythera Biopharmaceuticals Inc (KYTH) And Stock Analysis Report
The ratio turned negative, as 34 funds sold all Kythera Biopharmaceuticals Inc shares owned while 23 reduced positions. 59 funds bought stakes while 57 increased positions.
Kythera Biopharmaceuticals, Inc. (KYTH) Hits New 52-week Low During October ...
Momentum Stock in Focus: Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH)
Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) has been given a top momentum style rating by Zacks Research. This rating is an indicator of when a stock might be favorable to enter a position to take advantage of the equity movement in either an upward ...
Kythera Biopharmaceuticals Inc (KYTH) Discloses Form 4 Insider Selling ...  OTC Outlook
The Insider, John Smither Unloaded 53835 Shares of Kythera Biopharmaceuticals ...
As revealed in the Washington-based SEC, a document for the trade of 53,835 shares of Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) 74.98 0.00 % by John Smither was filled.
Zacks Short Term Rating on Kythera Biopharmaceuticals, Inc.
Analysts at Zacks have given a short term rating of hold on Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) with a rank of 3. The shares have received an average rating of 1.5 from 4 brokerage firms.
Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) Expected to report $-1.38 ...  Markets Daily
KYTHERA(R) Biopharmaceuticals Submits Investigational New Drug Application ...  CNNMoney